December 10th & 11th, 2026
15th edition
MARSEILLE, FR

Pre-money venture valuation: How to reach a fair agreement?

Edition

Pre-money venture valuation: How to reach a fair agreement?

There is usually a big disparity between investors and entrepreneurs regarding the valuation of an early-stage biotech company. How to determine what a company is actually worth? How do funds price the assets? What are the biases from each side? What are the points of negotiation?

Sharon Cunningham

CEO
Shorla Pharma

Robert Tansley

Partner
Cambridge Innovation Capital

Eliott Harfouche

Managing Partner
Nodes Advisors

Arnaud Autret

Investment Principal
M Ventures

Ivan Burkov

Senior Associate, Healthcare Team
INKEF Capital
Scroll to Top

Before you leave…

Download the official BioFIT 2026 brochure

Discover the conference programme, partnership opportunities, attendee profiles, registration options and everything you need to make the most of BioFIT 2026.